The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started
Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer.
Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.
Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and/or IO monotherapy or as a combination therapy.
High risk of bone fractures
Inability to physical exertion and/or unsuitability for cancer drug treatment
Poor co-operation ability for psychological reasons
Active use of cholesterol-lowering drugs
Tampere University Hospital
Lead sponsor
Tampere University
Collaborator
Aalto University
Collaborator
University of Helsinki
Collaborator
University of Turku
Collaborator